Advanced GI Immunology & IBD Pathogenesis

Peyer patches concentrate in the terminal ileum — the same site where ileal Crohn’s disease predominates. This anatomic coincidence is not accidental: antigen sampling and immune activation are maximal exactly where Crohn’s initiates.

Paneth cell metaplasia in a colonic biopsy is a strong histologic marker of chronicity — acute self-limiting colitis does not induce it. Its presence distinguishes IBD from infectious colitis even when architecture appears preserved.

The NOD2 p.R702W, p.G908R, and p.L1007fs variants triple the risk of ileal fibrostenotic Crohn’s disease. They impair macrophage handling of muramyl dipeptide, leading to persistent bacterial sensing and the chronic inflammation that characterizes classic Crohn’s phenotype.

The α4β7/MAdCAM-1 axis is gut-selective — this is the mechanistic reason vedolizumab has cleaner systemic safety than TNF or JAK inhibitors. It is the drug of choice whenever systemic immunosuppression must be minimized (e.g., elderly, cancer history).

Dietary vitamin A deficiency — common in refugee and vulnerable Saudi pediatric populations — impairs CD103+ DC retinoic acid production, weakens peripheral Treg induction, and measurably increases IBD susceptibility in animal models. Screen serum vitamin A in pediatric IBD.

Mucosal healing is necessary but not sufficient. Tissue-resident memory T cells persist for months to years after endoscopic remission and drive the 40-50% relapse rate seen when biologics are withdrawn. This is why STRIDE-II recommends against therapy discontinuation in most patients.

A primary non-responder to anti-TNF is best switched out of class (vedolizumab, ustekinumab, or JAK depending on phenotype). A secondary loss-of-responder with sub-therapeutic trough and no ADA needs dose optimization; with high ADA and low trough, switch within or out of class.

p19-selective (risankizumab, mirikizumab, guselkumab) appears to outperform p40-blocking (ustekinumab) on endoscopic and histologic endpoints in head-to-head network meta-analyses. For a biologic-naïve patient with luminal CD and moderate-severe UC, p19-selective agents are increasingly first-line.

Upadacitinib is the fastest-acting oral agent in UC — 15% of patients achieve clinical remission by day 8 at the 45 mg induction dose. In steroid-refractory acute severe UC, it is a viable alternative to infliximab rescue in centers comfortable with JAK use.

Vedolizumab is the cleanest biologic from a systemic infection and malignancy standpoint. For IBD patients aged ≥60, with cancer history, transplant candidates, or significant comorbidity, gut-selective α4β7 blockade is the safest choice — even if efficacy is slightly lower than anti-TNF in some scenarios.

NOD2 testing is not routinely recommended in clinical practice: positive predictive value for disease is low in the general population, and knowing the variant does not currently change treatment. Reserve it for research cohorts and unusual phenotypes (early-onset fibrostenotic ileal CD in consanguineous families).

IL-23R R381Q is the archetypal example of genetics driving drug development. The observation that a naturally occurring loss-of-function variant is protective against IBD was the single strongest argument for pharmacologically blocking IL-23 — now validated by four approved biologics.

Polygenic risk scores are not yet clinically actionable — but they are coming. Within 5-10 years, expect IBD PRS to stratify biologic selection (which class will work best?), surgical risk, and who to enroll in prevention trials for first-degree relatives of probands.

In the Saudi population, where consanguinity rates are high, NUDT15 R139C is the most important pharmacogenetic test before starting thiopurines. Homozygotes have >90% risk of severe bone-marrow suppression at standard doses. Order it alongside (not instead of) TPMT — they catch different patients.

Butyrate from Faecalibacterium prausnitzii is the single most important microbial metabolite in the colon. It fuels colonocytes (80% of their energy), inhibits HDACs to stabilize FOXP3 in Tregs, and strengthens tight junctions. Its loss in IBD is both a marker and a driver of disease.

Adherent-invasive E. coli (AIEC) is disproportionately expanded in ileal Crohn’s disease and is mechanistically linked to NOD2/ATG16L1 defects in intracellular bacterial clearance. Saudi ileal CD patients show particularly high AIEC colonization rates — a local target for future microbiome-directed therapy.

FMT for UC has positive RCT evidence but is NOT yet standard of care. Reserve it for mild-moderate UC in patients who have failed conventional therapy and want to avoid biologics, in centers with established donor screening programs under IRB oversight.

For every Saudi IBD patient, give three simple dietary instructions: (1) minimize ultra-processed foods and industrial emulsifiers, (2) adopt a Mediterranean-leaning pattern, (3) discuss CDED with a trained dietitian if pediatric mild-moderate CD. Do not over-promise — diet is adjunctive, not replacement, for medical therapy.

When you read a GWAS paper, always ask: (1) what is the effect size per locus (most are OR <1.3, so they predict poorly for individuals), (2) is the ancestry representative of your patients, and (3) is there a functional mechanism — not just an association — linking the variant to disease? Jostins 2012 passes the first two but leaves the third to follow-up work.

Gevers 2014 is the paper to cite when a colleague says "dysbiosis in IBD is just a consequence of inflammation." The data come from treatment-naïve new-onset patients. It does not prove causation — but it dismantles the simplest reactive-only model.

Paramsothy 2017 changed FMT in UC from "promising case series" to "evidence-based intervention." But NNT of 5 with a complex delivery protocol, variable donor quality, and uncertain long-term durability means FMT remains a research intervention in most Saudi centers — offer it only within IRB-approved protocols.

The single most important question at journal club is not "is the paper good?" but "would I change my Saudi patient’s management based on it?" If the cohort, comorbidities, and context don’t match your patients, even a high-quality paper should not change practice immediately.